XML 38 R34.htm IDEA: XBRL DOCUMENT
v3.20.1

Reverse Merger - Additional Information (Detail) $ / shares in Units, $ in Thousands |  |  | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
May 23, 2018 | Aug. 01, 2017 Year Right $ / shares shares | Dec. 31, 2017 USD ($) | Dec. 31, 2019 shares | Dec. 31, 2018 shares
Business Acquisition [Line Items] |  |  |  |  |
Reverse stock split ratio | 0.1 |  |  |  |
Common stock, shares outstanding | shares |  |  |  | 29,485,178 | 6,721,117
Contingent value rights recovery | $ |  |  | $ 200 |  |
OncoGenex Pharmaceuticals, Inc [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Reverse stock split ratio |  | 0.0909 |  |  |
Share price | $ / shares |  | $ 46.20 |  |  |
Common stock, shares outstanding | shares |  | 273,670 |  |  |
Number of contingent value rights to be issued for each share of common stock outstanding | Right |  | 1 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Contingent Value Rights [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Combined company acquisition period results |  | 5 years |  |  |
Aggregate consideration distributed to the holders, consideration received percent |  | 80.00% |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Price [Member] | Warrant [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of outstanding warrants, assumptions |  | 46.20 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Minimum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of outstanding warrants, assumptions |  | 1.32 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Maximum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of outstanding warrants, assumptions |  | 1.53 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Minimum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of outstanding warrants, assumptions |  | 1 year 10 months 28 days |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Maximum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of outstanding warrants, assumptions |  | 3 years 2 months 26 days |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Minimum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of outstanding warrants, assumptions |  | 90.33 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Maximum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of outstanding warrants, assumptions |  | 106.08 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Stock Price [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of stock options, assumptions |  | 46.20 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Minimum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of stock options, assumptions |  | 97.23 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Maximum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of stock options, assumptions |  | 106.63 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Minimum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of stock options, assumptions |  | 1.31 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Maximum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of stock options, assumptions |  | 1.54 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Minimum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of stock options, assumptions | Year |  | 1.82 |  |  |
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Maximum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value of stock options, assumptions | Year |  | 3.31 |  |  |

X
- Definition Business combination contingent consideration arrangements, percentage payable to consideration rights holders. + References No definition available. + Details
Name: | achv_BusinessCombinationContingentConsiderationArrangementsPercentagePayableToConsiderationRightsHolders
Namespace Prefix: | achv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent value rights liability recovery. + References No definition available. + Details
Name: | achv_ContingentValueRightsLiabilityRecovery
Namespace Prefix: | achv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of contingent value rights to be issued for each share of common stock outstanding. + References No definition available. + Details
Name: | achv_NumberOfContingentValueRightsToBeIssuedForEachShareOfCommonStockOutstanding
Namespace Prefix: | achv_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Value of input used to measure alternative investment. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_AlternativeInvestmentMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period when results of operations of the acquired entity are included in the income statement of the combined entity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionPeriodResultsIncludedInCombinedEntity1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockSharesOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingMeasurementInput
Namespace Prefix: | us-gaap_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=achv_OncoGenexPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=achv_ContingentValueRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=achv_WarrantLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |